BioMarin Pharmaceutical (BMRN)Officer sold ~$1.6M

~$1.6M

Approx. value · 26K sh @ $61.36

72K

Holds after · shares reported

Traded

Feb 26, 2026

Filed

Feb 27, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 12, 2026Company filing · Form 8-K · ResultsReported its results
2. Jan 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)
3. Feb 12, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
4. Feb 23, 2026Company filing · Form 8-K · ResultsReported its results
5. Feb 26, 2026 · this disclosureInsiderOfficer sold ~$1.6M of BMRN shares in the open market

What came next

1. Feb 26, 2026InsiderOfficer sold ~$382K of BMRN shares in the open market
2. Mar 11, 2026InsiderOfficer sold ~$997K of BMRN shares in the open market
3. Apr 27, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement (and 2 more items)“The information set forth in the “Introductory Note” above is incorporated into this Item 2.01 by reference.”
4. May 4, 2026Company filing · Form 8-K · ResultsReported its results
5. May 7, 2026InsiderOfficer sold ~$177K of BMRN shares in the open market
6. Jun 2, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 2, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the Company) held its 2026 Annual Meeting of Stockholders (the Annual Meeting).”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for BioMarin Pharmaceutical

For BioMarin Pharmaceutical, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BMRN page.

Other recent filings by George Eric Davis, EVP, Chief Legal Officer

• SEC Form 4 at BioMarin Pharmaceutical (BMRN)Sep 3, 2026

The full history of George Eric Davis, EVP, Chief Legal Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at BioMarin Pharmaceutical

• SEC Form 4Sep 3, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its BMRN page.